Edwards Lifesciences (NYSE:EW) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Edwards Lifesciences (NYSE:EW) had its price objective increased by Robert W. Baird from $83.00 to $88.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “neutral” rating on the medical research company’s stock. Robert W. Baird’s target price would suggest a potential upside of 2.66% from the company’s previous close.

A number of other equities research analysts also recently issued reports on the company. Oppenheimer downgraded Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. Evercore ISI lifted their price objective on Edwards Lifesciences from $88.00 to $92.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Raymond James Financial raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price on the stock in a report on Monday, November 3rd. UBS Group restated a “neutral” rating on shares of Edwards Lifesciences in a research report on Wednesday. Finally, Canaccord Genuity Group reaffirmed a “hold” rating on shares of Edwards Lifesciences in a research note on Friday. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $92.09.

Edwards Lifesciences Price Performance

NYSE:EW opened at $85.72 on Friday. Edwards Lifesciences has a 52 week low of $65.94 and a 52 week high of $87.40. The firm has a market cap of $49.74 billion, a price-to-earnings ratio of 36.95, a P/E/G ratio of 3.72 and a beta of 0.97. The firm’s 50-day simple moving average is $80.75 and its 200 day simple moving average is $78.68. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the previous year, the firm posted $0.67 EPS. The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, sell-side analysts predict that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the sale, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,314,725.84. This trade represents a 24.58% decrease in their position. The SEC filing for this sale provides additional information. 1.29% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in EW. JPL Wealth Management LLC bought a new position in Edwards Lifesciences in the third quarter worth approximately $25,000. Rosenberg Matthew Hamilton purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter worth $28,000. Quantbot Technologies LP purchased a new position in Edwards Lifesciences during the first quarter valued at $26,000. True Wealth Design LLC grew its holdings in Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares during the period. Finally, NewSquare Capital LLC increased its position in Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after buying an additional 134 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.